These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

564 related articles for article (PubMed ID: 25349172)

  • 41. Diagnostic and therapeutic biomarkers for Alzheimer's disease in human-derived platelets.
    Min JW; Lee J; Mun HJ; Kim DH; Park BG; Yoon B; Ryu JH; Cho HJ
    Genes Genomics; 2020 Dec; 42(12):1467-1475. PubMed ID: 33180258
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Increased number of circulating exosomes and their microRNA cargos are potential novel biomarkers in alcoholic hepatitis.
    Momen-Heravi F; Saha B; Kodys K; Catalano D; Satishchandran A; Szabo G
    J Transl Med; 2015 Aug; 13():261. PubMed ID: 26264599
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Utility of an Alzheimer's Disease Risk-Weighted Polygenic Risk Score for Predicting Rates of Cognitive Decline in Preclinical Alzheimer's Disease: A Prospective Longitudinal Study.
    Porter T; Burnham SC; Milicic L; Savage G; Maruff P; Lim YY; Li QX; Ames D; Masters CL; Rainey-Smith S; Rowe CC; Salvado O; Groth D; Verdile G; Villemagne VL; Laws SM;
    J Alzheimers Dis; 2018; 66(3):1193-1211. PubMed ID: 30412495
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The combination of apolipoprotein E4, age and Alzheimer's Disease Assessment Scale - Cognitive Subscale improves the prediction of amyloid positron emission tomography status in clinically diagnosed mild cognitive impairment.
    Ba M; Ng KP; Gao X; Kong M; Guan L; Yu L;
    Eur J Neurol; 2019 May; 26(5):733-e53. PubMed ID: 30561868
    [TBL] [Abstract][Full Text] [Related]  

  • 45. APOE genetic variants and apoE, miR-107 and miR-650 levels in Alzheimer's disease.
    Prendecki M; Florczak-Wyspianska J; Kowalska M; Ilkowski J; Grzelak T; Bialas K; Kozubski W; Dorszewska J
    Folia Neuropathol; 2019; 57(2):106-116. PubMed ID: 31556571
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Peripheral Blood MicroRNA Expression Profiles in Alzheimer's Disease: Screening, Validation, Association with Clinical Phenotype and Implications for Molecular Mechanism.
    Ren RJ; Zhang YF; Dammer EB; Zhou Y; Wang LL; Liu XH; Feng BL; Jiang GX; Chen SD; Wang G; Cheng Q
    Mol Neurobiol; 2016 Oct; 53(8):5772-81. PubMed ID: 26497032
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Enabling a multidisciplinary approach to the study of ageing and Alzheimer's disease: an update from the Australian Imaging Biomarkers and Lifestyle (AIBL) study.
    Ellis KA; Rainey-Smith SR; Rembach A; Macaulay SL; Villemagne VL;
    Int Rev Psychiatry; 2013 Dec; 25(6):699-710. PubMed ID: 24423223
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Addressing population aging and Alzheimer's disease through the Australian imaging biomarkers and lifestyle study: collaboration with the Alzheimer's Disease Neuroimaging Initiative.
    Ellis KA; Rowe CC; Villemagne VL; Martins RN; Masters CL; Salvado O; Szoeke C; Ames D;
    Alzheimers Dement; 2010 May; 6(3):291-6. PubMed ID: 20451879
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Validation of AclarusDx™, a blood-based transcriptomic signature for the diagnosis of Alzheimer's disease.
    Fehlbaum-Beurdeley P; Sol O; Désiré L; Touchon J; Dantoine T; Vercelletto M; Gabelle A; Jarrige AC; Haddad R; Lemarié JC; Zhou W; Hampel H; Einstein R; Vellas B;
    J Alzheimers Dis; 2012; 32(1):169-81. PubMed ID: 22785402
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Exosomal miRNA profile as complementary tool in the diagnostic and prediction of treatment response in localized breast cancer under neoadjuvant chemotherapy.
    Rodríguez-Martínez A; de Miguel-Pérez D; Ortega FG; García-Puche JL; Robles-Fernández I; Exposito J; Martorell-Marugan J; Carmona-Sáez P; Garrido-Navas MDC; Rolfo C; Ilyine H; Lorente JA; Legueren M; Serrano MJ
    Breast Cancer Res; 2019 Feb; 21(1):21. PubMed ID: 30728048
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Integrated analysis of miRNA and mRNA expression in the blood of patients with Alzheimer's disease.
    Wang Z; Shen L; Wang Y; Huang S
    Mol Med Rep; 2020 Aug; 22(2):1053-1062. PubMed ID: 32468026
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A blood-based predictor for neocortical Aβ burden in Alzheimer's disease: results from the AIBL study.
    Burnham SC; Faux NG; Wilson W; Laws SM; Ames D; Bedo J; Bush AI; Doecke JD; Ellis KA; Head R; Jones G; Kiiveri H; Martins RN; Rembach A; Rowe CC; Salvado O; Macaulay SL; Masters CL; Villemagne VL; ;
    Mol Psychiatry; 2014 Apr; 19(4):519-26. PubMed ID: 23628985
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Evolving Evidence for the Value of Neuroimaging Methods and Biological Markers in Subjects Categorized with Subjective Cognitive Decline.
    Lista S; Molinuevo JL; Cavedo E; Rami L; Amouyel P; Teipel SJ; Garaci F; Toschi N; Habert MO; Blennow K; Zetterberg H; O'Bryant SE; Johnson L; Galluzzi S; Bokde AL; Broich K; Herholz K; Bakardjian H; Dubois B; Jessen F; Carrillo MC; Aisen PS; Hampel H
    J Alzheimers Dis; 2015 Sep; 48 Suppl 1():S171-91. PubMed ID: 26402088
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparison of CSF markers and semi-quantitative amyloid PET in Alzheimer's disease diagnosis and in cognitive impairment prognosis using the ADNI-2 database.
    Ben Bouallègue F; Mariano-Goulart D; Payoux P;
    Alzheimers Res Ther; 2017 Apr; 9(1):32. PubMed ID: 28441967
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Plasma biomarkers associated with the apolipoprotein E genotype and Alzheimer disease.
    Soares HD; Potter WZ; Pickering E; Kuhn M; Immermann FW; Shera DM; Ferm M; Dean RA; Simon AJ; Swenson F; Siuciak JA; Kaplow J; Thambisetty M; Zagouras P; Koroshetz WJ; Wan HI; Trojanowski JQ; Shaw LM;
    Arch Neurol; 2012 Oct; 69(10):1310-7. PubMed ID: 22801723
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Can Peripheral MicroRNA Expression Data Serve as Epigenomic (Upstream) Biomarkers of Alzheimer's Disease?
    Yılmaz ŞG; Erdal ME; Özge AA; Sungur MA
    OMICS; 2016 Aug; 20(8):456-61. PubMed ID: 27501295
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Changes in plasma amyloid beta in a longitudinal study of aging and Alzheimer's disease.
    Rembach A; Faux NG; Watt AD; Pertile KK; Rumble RL; Trounson BO; Fowler CJ; Roberts BR; Perez KA; Li QX; Laws SM; Taddei K; Rainey-Smith S; Robertson JS; Vandijck M; Vanderstichele H; Barnham KJ; Ellis KA; Szoeke C; Macaulay L; Rowe CC; Villemagne VL; Ames D; Martins RN; Bush AI; Masters CL;
    Alzheimers Dement; 2014 Jan; 10(1):53-61. PubMed ID: 23491263
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.
    Li QX; Villemagne VL; Doecke JD; Rembach A; Sarros S; Varghese S; McGlade A; Laughton KM; Pertile KK; Fowler CJ; Rumble RL; Trounson BO; Taddei K; Rainey-Smith SR; Laws SM; Robertson JS; Evered LA; Silbert B; Ellis KA; Rowe CC; Macaulay SL; Darby D; Martins RN; Ames D; Masters CL; Collins S;
    J Alzheimers Dis; 2015; 48(1):175-87. PubMed ID: 26401938
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Multivariate protein signatures of pre-clinical Alzheimer's disease in the Alzheimer's disease neuroimaging initiative (ADNI) plasma proteome dataset.
    Johnstone D; Milward EA; Berretta R; Moscato P;
    PLoS One; 2012; 7(4):e34341. PubMed ID: 22485168
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Dysregulation and diagnostic potential of microRNA in Alzheimer's disease.
    Pan Y; Liu R; Terpstra E; Wang Y; Qiao F; Wang J; Tong Y; Pan B
    J Alzheimers Dis; 2016; 49(1):1-12. PubMed ID: 26484912
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.